A recent FDA advisory panel vote has cast a long shadow over peptide research and access. On 30 April 2025, the panel voted 16-1 that oral BPC-157 should not be permitted as a dietary ingredient. The immediate consequence is a likely enforcement wave that will push many peptide products off the open market. For researchers and clinicians tracking rotator cuff repair, the vote raises a practical question: what does the evidence actually say about BPC-157 and IGF-1 LR3 for tendon healing, and how should the community interpret the regulatory shift?
No content in this article should be interpreted as personalised medical guidance. The discussion that follows examines preclinical and clinical data on two peptides that have attracted attention for soft-tissue repair, with a focus on rotator cuff injury. The goal is to separate signal from noise while acknowledging the real constraints the FDA vote imposes.
Why the rotator cuff is a stubborn healing problem
The rotator cuff is a confluence of four tendons that wrap the humeral head. Its blood supply is notoriously poor, especially in the critical zone near the supraspinatus insertion. After surgical repair, re-tear rates remain stubbornly high. A 2012 systematic review in Arthroscopy by McElvany and colleagues put the overall re-tear rate at something like 26% for small tears and over 90% for massive tears. Even with modern double-row fixation, the biology of the tendon-bone interface often fails before the suture anchors do.
That biological bottleneck is what makes peptide-based adjuncts interesting. The idea is not to replace mechanical fixation but to accelerate the cellular processes that turn a surgical repair into a durable enthesis. Two compounds that keep surfacing in this context are BPC-157, a pentadecapeptide derived from gastric juice, and IGF-1 LR3, a long-acting analogue of insulin-like growth factor 1.
BPC-157: what the animal data show for tendon repair
BPC-157 has been studied in dozens of rodent models of tendon injury. A 2011 paper by Chang and colleagues in Journal of Orthopaedic Research used a rat Achilles tendon transection model and reported that BPC-157 delivered via drinking water improved functional recovery and increased fibroblast density at the repair site. The treated tendons showed higher collagen type I expression and better alignment of collagen fibrils compared to controls. The effect size was not subtle: tensile strength in the BPC-157 group reached roughly 70% of uninjured tendon by day 14, versus about 40% in controls.
More relevant to the rotator cuff, a 2017 study by Krivic and colleagues in International Orthopaedics examined BPC-157 in a rat supraspinatus detachment-repair model. The peptide was administered intraperitoneally for two weeks post-surgery. At four weeks, the BPC-157 group showed increased vascular endothelial growth factor (VEGF) expression and a higher proportion of mature collagen at the tendon-bone interface. The authors suggested that BPC-157 promotes angiogenesis during the early phase of healing, which may be critical given the hypovascular nature of the rotator cuff insertion.
Mechanistically, BPC-157 is thought to upregulate growth hormone receptors and potentiate the effects of endogenous growth factors. A 2016 review by Sikiric and colleagues in Current Pharmaceutical Design catalogued evidence that BPC-157 interacts with the nitric oxide system and modulates the expression of early growth response genes. The review is worth reading for anyone who wants to understand the breadth of the preclinical literature, though it carries the usual caveat that most data come from a single research group.
What is conspicuously absent is human trial data for rotator cuff repair. A handful of small clinical studies have examined oral BPC-157 for inflammatory bowel disease, but tendon healing in humans remains unstudied in a controlled setting. That gap is part of what troubled the FDA panel: without human safety and efficacy data, the leap from rodent tendon to human rotator cuff is a long one.
IGF-1 LR3: a longer half-life for a familiar growth factor
IGF-1 is a well-characterised mediator of muscle and tendon hypertrophy. Native IGF-1 has a half-life measured in minutes, largely because it is bound by IGF-binding proteins in circulation. IGF-1 LR3 is a recombinant analogue with an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These modifications reduce binding to IGF-binding proteins and extend the half-life to something like 20-30 hours in rodents.
In the context of tendon repair, IGF-1 LR3 has been studied mostly in cell culture and animal models. A 2008 paper by Docheva and colleagues in Journal of Biological Chemistry showed that IGF-1 promotes tenocyte proliferation and collagen synthesis in vitro. The LR3 analogue was not used in that particular study, but the signalling pathway (PI3K/Akt) is the same. A 2015 study by Disser and colleagues in American Journal of Sports Medicine used a rat supraspinatus repair model and found that local delivery of IGF-1 via a fibrin matrix improved collagen organisation and reduced scar formation at the enthesis. Again, this was native IGF-1, not the LR3 analogue, but the principle is similar.
The appeal of stacking BPC-157 with IGF-1 LR3 is based on a complementary-mechanism hypothesis. BPC-157 may improve vascularisation and early fibroblast recruitment, while IGF-1 LR3 could sustain tenocyte proliferation and matrix synthesis over a longer window. No published study has tested this combination in a rotator cuff model, so the hypothesis remains speculative. A related concept is explored in research on BPC-157 and Thymosin Alpha-1 for muscle repair, where complementary mechanisms are similarly invoked.
What the FDA panel vote actually decided
The 30 April 2025 vote addressed a narrow question: whether oral BPC-157 meets the definition of a dietary ingredient under the Federal Food, Drug, and Cosmetic Act. The panel concluded it does not. The reasoning centred on the fact that BPC-157 was first studied as a pharmaceutical and has never been marketed as a food or supplement prior to its drug investigations. Under the FD&C Act, an article that is first studied as a drug cannot later be sold as a dietary ingredient unless it was marketed as a food or supplement before the drug investigations began.
The practical effect is that the FDA now has a clear advisory opinion to support enforcement actions against companies selling oral BPC-157 as a supplement. Injectable formulations are in a greyer area, but the panel's reasoning could easily extend to any route of administration. The vote does not ban research; it constrains commercial distribution. Researchers with an approved IND can still obtain BPC-157 for clinical studies, but the grey-market supply that many clinics and individuals have relied on will likely contract sharply.
For IGF-1 LR3, the situation is different. IGF-1 LR3 has never been the subject of an FDA advisory panel vote, but it falls under the same legal framework. Because it is a synthetic analogue of a naturally occurring hormone and has been investigated as a drug, it is unlikely to qualify as a dietary ingredient. Enforcement has been sporadic, but the BPC-157 vote signals a broader willingness to apply the drug-first exclusion principle to peptide products.
Other peptides that appear in the rotator cuff conversation
While BPC-157 and IGF-1 LR3 dominate the discussion, a few other peptides deserve mention. GHK-Cu is a copper-binding tripeptide that has been studied for wound healing and tissue remodelling. A 2018 paper by Pickart and colleagues in BioMed Research International reviewed its effects on collagen synthesis and its ability to attract immune cells to injury sites. GHK-Cu is sometimes combined with KPV, a tripeptide with anti-inflammatory properties, for skin wound healing. The logic for rotator cuff repair is similar: reduce early inflammation and promote organised collagen deposition. A recent article on GHK-Cu and KPV for accelerating skin wound healing covers the preclinical data in detail.
Pentadeca Arginate, a 15-amino-acid fragment of BPC-157, has been marketed as a more stable alternative, but the published literature is thin. Thymosin Alpha-1 is primarily an immune modulator and has no direct evidence in tendon repair, though it appears in some stack protocols aimed at reducing post-surgical inflammation. The connection between gut health and joint recovery is also gaining attention. An article on BPC-157 and the gut-joint axis in athletes on GLP-1 agonists explores how systemic inflammation and nutrient absorption may influence tendon healing.
Reading the regulatory tea leaves
The FDA panel vote is not a final rule, but it is a strong signal. Companies that continue to sell oral BPC-157 as a dietary ingredient are now operating against an explicit advisory opinion. The agency has a range of enforcement tools, from warning letters to injunctions, and it has shown a willingness to use them against peptide sellers in the past. The vote may also influence compounding pharmacies, which have been a source of injectable BPC-157 for some clinics. If the FDA classifies BPC-157 as an unapproved new drug, compounding from bulk substances becomes more difficult to justify under section 503A of the FD&C Act.
For researchers, the path forward is clear: an approved IND is the only reliable way to study BPC-157 in humans. The preclinical data are strong enough to justify that investment, especially for rotator cuff repair, where the clinical need is large and the current standard of care leaves room for improvement. A well-designed phase I/II trial of BPC-157 with or without IGF-1 LR3 in arthroscopic rotator cuff repair patients would answer many of the open questions. Whether any sponsor will take that on is another matter. Peptides are difficult to patent, and the commercial incentive for a trial that could cost tens of millions of dollars is uncertain.
In the meantime, the stack hypothesis remains just that. The animal data for BPC-157 are encouraging, and the mechanistic rationale for adding IGF-1 LR3 is plausible. But without human data, the gap between rodent supraspinatus and human rotator cuff is wide. The FDA panel vote does not change the science, but it does change the accessibility. Treatment of any condition is outside the scope of this article. Diagnosis and care should be conducted by a licensed practitioner.
What the next few years might look like
If enforcement follows the panel vote, the immediate effect will be a reduction in the number of people using BPC-157 outside of clinical trials. That could paradoxically slow the accumulation of anecdotal evidence, which has been a major driver of interest in the peptide. On the other hand, a clearer regulatory boundary might push serious researchers toward the IND pathway, which would ultimately produce higher-quality data. The rotator cuff community has been here before with platelet-rich plasma and stem cell therapies: early enthusiasm, a wave of off-label use, and then a gradual sorting of what works from what does not.
For now, the best reading of the evidence is that BPC-157 and IGF-1 LR3 are promising but unproven adjuncts for rotator cuff repair. The FDA panel vote is a reminder that the regulatory framework treats them as drugs, not supplements. Anyone considering these compounds should understand that the legal and scientific landscapes are both shifting. The next chapter will be written by researchers willing to do the human trials, not by the grey market.